mitochondrial peptides Archives

Tag Archive for: mitochondrial peptides

Peptides in Basic Cell Biology: How GLP, GHRH, and Mitochondrial Peptides Are Used to Probe Cellular Signaling Pathways

August 25, 2026/0 Comments/in Uncategorized/by

Fewer than two decades ago, researchers had limited molecular tools to dissect the difference between a receptor's metabolic function and its stress-response behavior. Today, peptides in basic cell biology, specifically how GLP, GHRH, and mitochondrial peptides are used to probe cellular signaling pathways, have become one of the most productive strategies in preclinical research. These molecules are not just therapeutic candidates; they are precision instruments for interrogating how cells sense, respond, and adapt at the molecular level.

Key Takeaways

GLP-1 analogs and GLP-3 compounds serve as selective probes for separating cAMP-driven metabolic signaling from beta-arrestin-mediated stress responses in cultured cells.
GHRH analogs, including tesa and CJC-1295, activate dual intracellular pathways in non-pituitary tissues, making them valuable tools for cancer and metabolic signaling research.
Mitochondrial peptides, MOTS-c, Humanin, and SS-31, target distinct organelle-level signaling nodes, including AMPK, STAT3, and cardiolipin-associated pathways.
Biased agonism at GPCRs can now be mapped using peptide probes designed to favor one downstream branch over another.
Research-grade purity and verified composition are essential when using these peptides as signaling tools in cell-based assays.

GLP Peptides as Probes of Receptor-Level Signaling Architecture

The glucagon-like peptide family has moved well beyond its association with insulin secretion. In 2026, the structural pharmacology of the GLP-1 receptor (GLP-1R) has been mapped in enough detail that researchers can now design experiments that selectively activate one downstream branch while suppressing another, a technique called biased agonism.

When GLP-1 analogs bind GLP-1R, two major intracellular cascades compete for activation:

cAMP/PKA pathway, classically linked to insulin secretion and metabolic regulation
Beta-arrestin pathway, associated with receptor internalization, ER stress responses, and apoptosis signaling

By using structurally distinct GLP-1 analogs, cell biologists can isolate which pathway drives a given phenotype. GLP-3 analogs extend this toolkit further, offering receptor-selectivity profiles that differ from GLP-1, allowing researchers to probe metabolic versus non-metabolic signaling in the same cell line without cross-activation. For researchers sourcing these tools, GLP-1 peptides must meet strict purity standards to produce reproducible assay results.

A comprehensive overview of how these molecules interact at the receptor and cellular level is available in the guide to peptide mechanisms from GLP-3 and retatrutide to CJC-1295 and MOTS-c, which outlines the mechanistic distinctions between family members.

GLP-1R as a stress-pathway sensor has also gained attention. Updated research in 2026 confirms that GLP-1R agonists can modulate ER stress markers and apoptosis regulators in pancreatic beta cells and neuronal cultures, independent of their glucose-lowering effects. This makes them dual-purpose probes: metabolic readouts and stress-biology readouts from the same receptor system.

"The ability to separate cAMP signaling from beta-arrestin recruitment at GLP-1R has transformed it from a therapeutic target into a precision cell biology instrument."

For a detailed breakdown of GLP-1, GLP-2, and GLP-3 distinctions, the researcher's guide to the GLP peptide family provides structured comparisons of receptor binding and downstream effects.

GHRH Analogs: Dual-Pathway GPCR Probes in Non-Pituitary Tissues

Growth hormone-releasing hormone (GHRH) and its receptor (GHRHR) were once studied almost exclusively in pituitary biology. Research from 2025 through 2026 has firmly established GHRHR as a dual-pathway GPCR expressed in multiple non-pituitary tissues, including lung, breast, prostate, and cardiac cells.

This broader expression profile makes GHRH analogs, particularly tesa and CJC-1295, highly useful as cell biology probes. When applied to cultured non-pituitary cells, these analogs activate:

Pathway	Key Effectors	Research Application
Gs/cAMP/PKA	CREB, gene transcription	Metabolic and proliferative signaling
MAPK/ERK1/2	Cell cycle regulators	Cancer signaling, apoptosis resistance

The ability to selectively engage one arm over the other, depending on analog structure, concentration, and cell type, gives researchers a controllable system for studying how GPCR signaling bifurcates inside the cell.

In cancer cell lines, GHRH analogs have been used to probe the balance between pro-survival and pro-apoptotic outputs from the same receptor. This has practical value for understanding how tumor cells co-opt hormonal signaling for growth. CJC-1295, a long-acting GHRH analog, is particularly useful in extended time-course experiments where sustained receptor occupancy is needed to observe downstream transcriptional changes.

Mitochondrial Peptides: MOTS-c, Humanin, and SS-31 as Organelle-Level Signaling Tools

The discovery that mitochondria encode their own bioactive peptides has opened an entirely new dimension in the study of peptides in basic cell biology: how GLP, GHRH, and mitochondrial peptides are used to probe cellular signaling pathways. Three peptides have emerged as primary research tools: MOTS-c, Humanin, and SS-31.

MOTS-c and AMPK-Centered Energy Stress Signaling

MOTS-c is encoded within the mitochondrial 12S rRNA gene and functions as a retrograde signal, moving from mitochondria to the nucleus in response to metabolic stress. In cell culture models, MOTS-c activates AMPK, the master energy sensor, and modulates folate and methionine metabolism. As of July 2026, MOTS-c is used to probe how cells detect and respond to nutrient deprivation and oxidative stress, making it a valuable tool for metabolic disease research.

Humanin and the gp130/STAT3 Survival Axis

Humanin activates a receptor complex involving gp130 and WSX-1, triggering STAT3 phosphorylation and downstream survival gene expression. Researchers use Humanin to map the boundary between cellular survival and apoptosis, particularly in neuronal and cardiac cell models. Its selectivity for this pathway makes it a clean probe for STAT3-dependent transcription without the off-target effects of cytokine stimulation.

SS-31: Cardiolipin Binding and Membrane Dynamics

SS-31 targets cardiolipin, a phospholipid unique to the inner mitochondrial membrane. By stabilizing cardiolipin-cytochrome c interactions, SS-31 helps researchers study how mitochondrial membrane integrity influences electron transport chain efficiency and reactive oxygen species (ROS) production. Detailed research applications are covered in the SS-31 mitochondrial dynamics resource and in SS-31 10mg research peptide considerations.

For researchers sourcing these tools, verified composition is non-negotiable. Lab tested peptides with documented certificates of analysis ensure that assay results reflect biology, not contaminant artifacts.

Conclusion

The use of peptides in basic cell biology, specifically how GLP, GHRH, and mitochondrial peptides are used to probe cellular signaling pathways, represents one of the most versatile and rapidly evolving areas of preclinical research in 2026. Each peptide class offers a distinct entry point into cell signaling: GLP analogs dissect GPCR bias at the receptor level, GHRH analogs map dual-pathway activation across tissue types, and mitochondrial peptides illuminate organelle-to-nucleus communication.

Actionable next steps for researchers:

Define the specific signaling node of interest before selecting a peptide probe, pathway selectivity is the primary selection criterion.
Use structurally characterized analogs (tesa, CJC-1295, MOTS-c) with documented receptor binding profiles to ensure experimental specificity.
Source only pure, tested peptides with third-party verified purity to maintain assay integrity.
Cross-validate findings using at least two peptide probes targeting the same pathway node to rule out off-target effects.
Consult current structural pharmacology data when designing biased agonism experiments at GLP-1R or GHRHR.

As mitochondrial peptide biology and GPCR structural pharmacology continue to converge, the toolkit available for dissecting cellular signaling will only grow more precise.

5-Amino-1MQ and MOTS-c Synergy in Adiposity Research: How Labs Stack Mitochondrial Peptides

August 16, 2026/0 Comments/in Uncategorized/by

Visceral fat accumulation drives metabolic disease more aggressively than subcutaneous fat, yet most research compounds target only one pathway at a time. The growing interest in combining 5-Amino-1MQ and MOTS-c synergy in adiposity research reflects a shift in how labs approach mitochondrial peptide stacking, moving from single-target interventions toward coordinated, multi-pathway designs that address the underlying bioenergetic dysfunction behind excess adiposity.

Key Takeaways

5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide, but is routinely co-studied with mitochondrial peptides because of its shared NAD+ framework.
MOTS-c activates AMPK and improves metabolic homeostasis, with particular relevance to visceral fat reduction in preclinical models.
The mechanistic rationale for stacking these two compounds is strong, but all current evidence is preclinical; no approved human indications exist as of 2026.
Researchers quantify synergy through specific outcome measures including AMPK phosphorylation, NAD+ levels, and body composition endpoints.
Combined stacks including SLUPP332 are emerging, but remain strictly research-use only pending safety and off-target risk clarification.

Understanding the Two Compounds Before Stacking

Before modeling a combined protocol, it is essential to understand what each compound actually does, and where common misconceptions arise.

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme responsible for consuming SAM (S-adenosylmethionine) and degrading NAD+ precursors in adipose tissue. By blocking NNMT, 5-Amino-1MQ elevates intracellular NAD+ and reduces adipocyte hypertrophy. In diet-induced obesity (DIO) mouse models, it has demonstrated measurable reductions in total adiposity without significant lean mass loss. A critical clarification: 5-Amino-1MQ is frequently mis-grouped as a "mitochondrial peptide" in popular research blogs, but it is a non-peptide small molecule. Its inclusion in peptide stacks is based on functional overlap within the NAD+/mitochondrial axis, not structural similarity.

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome, specifically within the 12S rRNA region. It is a true mitochondrial-derived peptide (MDP). Its primary mechanism involves activation of AMPK (AMP-activated protein kinase), the master metabolic regulator that promotes fatty acid oxidation, suppresses lipogenesis, and improves insulin sensitivity. Industry summaries in 2026 increasingly highlight its visceral-fat-targeting effects as a distinguishing feature among metabolic research peptides. For a broader overview of how MOTS-c is positioned alongside other mitochondrial compounds, see the MOTS-c and Elamipretide research overview.

Feature	5-Amino-1MQ	MOTS-c
Compound class	Small molecule	Mitochondrial peptide
Primary target	NNMT enzyme	AMPK pathway
Key metabolic effect	NAD+ elevation, fat cell reduction	Fatty acid oxidation, insulin sensitivity
Evidence base	DIO mouse models	Preclinical; human pilot data emerging
Route in research	Oral	Subcutaneous injection

Modeling Research Designs for 5-Amino-1MQ and MOTS-c Synergy in Adiposity Research

Most published synergy explainers stop at mechanism. A more useful framing for researchers involves modeling how a dual-compound study would actually be structured, including dose timing, sequencing, and how synergy is quantified rather than assumed.

Dose Timing and Sequencing Rationale

In preclinical adiposity models, the general design logic follows this sequence:

Baseline assessment (Week 0): Body composition via MRI or DEXA, fasting glucose, insulin, and tissue NAD+ levels established in DIO subjects.
MOTS-c administration (Weeks 1-4): Subcutaneous delivery to activate AMPK and prime mitochondrial fatty acid oxidation pathways before introducing the NNMT inhibitor.
5-Amino-1MQ introduction (Week 3 onward, overlapping): Oral administration begins while MOTS-c continues, allowing NAD+ elevation to amplify the metabolic environment already primed by AMPK activation.
Mid-study checkpoint (Week 4): AMPK phosphorylation assays, plasma NAD+ metabolomics, and adipose tissue biopsy for lipid droplet morphology.
Endpoint analysis (Week 8): Full body composition, visceral vs. subcutaneous fat volume, inflammatory cytokine panels, and methylation markers to monitor SAM/SAH ratios.

This staggered approach is mechanistically justified: MOTS-c's AMPK activation creates a catabolic metabolic state that may enhance the downstream effects of elevated NAD+ produced by NNMT inhibition. The two pathways are complementary rather than redundant.

Quantifying Synergy, Not Just Additive Effects

Researchers distinguish between additive and synergistic effects using the Bliss independence model or Loewe additivity framework. In a well-designed metabolic study, synergy would be demonstrated if the combined reduction in visceral fat volume exceeds the mathematical sum of each compound's individual effect at the same dose. Secondary markers for synergy include:

AMPK phosphorylation ratio (pAMPK/total AMPK) in adipose and liver tissue
Intracellular NAD+/NADH ratio in white adipose tissue
Adiponectin and leptin levels as functional adiposity biomarkers
Methylation index (SAM/SAH) to confirm NNMT inhibition without excessive methyl donor depletion

For researchers exploring how metabolic peptides are evaluated across different endpoints, the top 5 research peptides for metabolic health buyer's guide provides useful comparative context.

The Expanding Stack: SLUPP332, Evidence Gaps, and Research Outlook

The concept of the "NAD+/MOTS-c/5-Amino-1MQ mitochondrial longevity stack" has gained traction in 2026 research community discussions, with one notable expansion: SLUPP332, a synthetic REV-ERB agonist that regulates circadian metabolic rhythms, is now being included in advanced stack models alongside MOTS-c and 5-Amino-1MQ. The rationale is that circadian dysregulation compounds adiposity by disrupting the timing of mitochondrial biogenesis, a gap that neither NNMT inhibition nor AMPK activation directly addresses.

"Mechanistic promise is not clinical proof. Every current stack model involving 5-Amino-1MQ and MOTS-c remains explicitly hypothetical until controlled human trial data exists."

This caution is not pessimism, it is the appropriate scientific framing. As of mid-2026, no formal clinical trials have been completed for this compound combination. All stacking guidance circulating in research blogs is derived from mechanistic reasoning, not outcome data. Researchers interested in adjacent mitochondrial peptide comparisons may find the LL-37 versus SS-31 peptide benefits comparison useful for understanding how different mitochondrial-targeting peptides are differentiated in research settings.

Those sourcing MOTS-c for preclinical work should review dedicated sourcing resources such as the buy MOTS-c peptide sourcing page to ensure compound purity and certificate of analysis standards are met.

Key Evidence Gaps Researchers Must Address

NAD+/methylation crosstalk risk: NNMT inhibition affects SAM availability; prolonged inhibition could theoretically disrupt methylation-dependent processes. No long-term safety data exists.
Off-target AMPK effects: Systemic AMPK activation via MOTS-c may affect cardiac and skeletal muscle tissue in ways not yet characterized at combined doses.
Species translation: DIO mouse model results for 5-Amino-1MQ do not automatically translate to human adiposity phenotypes, which are metabolically more heterogeneous.

For researchers working within a broader metabolic peptide framework, the GLP-1 peptide generational research concepts and sourcing notes and the Retatrutide and MASLD triple-agonist research overview offer complementary perspectives on how multi-target metabolic strategies are being evaluated in 2026.

Conclusion

The intersection of 5-Amino-1MQ and MOTS-c synergy in adiposity research represents one of the more mechanistically coherent compound stacking concepts in current metabolic science. The logic is clear: NNMT inhibition elevates NAD+ while AMPK activation drives fat oxidation, and the two pathways reinforce each other within the mitochondrial bioenergetic framework.

Actionable next steps for researchers:

Design studies with staggered dosing (MOTS-c preceding 5-Amino-1MQ) to allow AMPK priming before NAD+ elevation.
Use Bliss independence or Loewe additivity models to formally test synergy rather than assuming it from mechanism alone.
Include methylation index (SAM/SAH) and AMPK phosphorylation assays as mandatory secondary endpoints.
Source compounds with verified certificates of analysis and maintain strict research-use-only protocols.
Monitor the literature for early human pilot trial data, which industry analysts expect to emerge within the next few years as preclinical evidence matures.

Until controlled human data is available, the stack remains a hypothesis worth testing rigorously, not a protocol ready for translation.

Peptides in Modern Research: From Simple Chains to Complex Polypeptide Hormones

August 15, 2026/0 Comments/in Uncategorized/by

More than 80 peptide-based drugs have received FDA approval to date, covering everything from endocrinology to oncology, and in 2026 alone, the pipeline holds over 150 additional candidates in active clinical development. That scale of activity signals something fundamental: the study of peptides in modern research, from simple chains to complex polypeptide hormones, has moved from a niche biochemical pursuit to one of the most productive frontiers in science.

Key Takeaways

Peptides range from two-amino-acid dipeptides to large, folded polypeptide hormones, and their size directly shapes their biological function and research utility.
The FDA approved oral semaglutide for chronic weight management in late 2025, and orforglipron followed in April 2026, both driven by polypeptide hormone biology.
Research compounds such as BPC-157, GHK-Cu, MOTS-c, and 5-Amino-1MQ represent distinct peptide classes with different mechanisms and experimental profiles.
Regulatory policy shifted in 2026, with 12 peptides removed from the FDA's restricted Category 2 compounding list, reshaping access for research applications.
Purity and sourcing quality remain critical variables in any peptide research program.

Classifying Peptides: Size, Structure, and Function

Understanding peptides in modern research, from simple chains to complex polypeptide hormones, starts with a clear classification framework. Not all peptides are alike. Their length, folding behavior, and receptor interactions differ significantly, and those differences determine what each compound can do in a research model.

Peptide size categories at a glance:

Category	Amino Acid Count	Examples
Dipeptide	2	Carnosine
Oligopeptide	3-10	BPC-157 fragment analogs
Polypeptide	10-50	GHK-Cu, MOTS-c
Polypeptide Hormone	50+	Semaglutide, PTH analogs

Short peptides, those with fewer than ten amino acids, tend to be more stable, easier to synthesize, and simpler to study in isolated cellular models. Longer polypeptides and hormone analogs introduce complexity: tertiary folding, disulfide bridges, and receptor-binding domains that require more sophisticated handling and storage protocols.

For a deeper look at how molecular size shapes experimental design, the article on peptides and polypeptides in modern research: how molecular size shapes function, stability, and experimental design provides a detailed structural breakdown.

"Peptide length is not just a chemical detail, it is a primary determinant of how a compound behaves in biological systems, how it is stored, and how it is interpreted in research data."

Key Research Peptide Classes in 2026

The landscape of peptides in modern research, from simple chains to complex polypeptide hormones, now spans several distinct compound classes. Each class serves different experimental goals.

Short and Mid-Length Research Peptides

BPC-157 is a synthetic pentadecapeptide derived from a gastric protein sequence. It has been studied extensively in tissue and wound models. Researchers interested in its documented profile can consult the BPC-157 core peptides documentation first research guide for a structured overview of its experimental applications.

GHK-Cu is a copper-binding tripeptide that has attracted attention in skin, collagen, and tissue research. Its copper-complex chemistry gives it unique stability considerations. The GHK-Cu peptide: copper complex chemistry, research stability, and lab use considerations article covers the handling nuances relevant to lab settings.

Mitochondrial Peptides

MOTS-c and 5-Amino-1MQ represent a newer class of metabolically active research compounds. MOTS-c is a mitochondria-derived peptide that influences insulin sensitivity and energy metabolism pathways. 5-Amino-1MQ is a small-molecule NNMT inhibitor often studied alongside MOTS-c in adiposity models. Their combined profile is explored in the article on 5-Amino-1MQ and MOTS-c synergy: how mitochondrial peptides target adiposity and insulin resistance in experimental models.

Polypeptide Hormone Analogs

This is the most clinically advanced category. GLP-1 receptor agonists such as semaglutide and dulaglutide are structurally engineered polypeptide hormones designed to mimic and extend the action of endogenous incretin hormones. Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, represents the next generation of multi-target hormone-mimetic design.

Emerging compounds like GLP-3 and GLP-2-T are also entering research discussions, reflecting how the incretin hormone family continues to expand as a research target. For context on how these naming conventions and compound categories are evolving, the GLP-2-T peptide and GLP-2 Tirz peptide: naming confusion, product labels, and research interpretation article addresses common points of confusion.

Regulatory Shifts and the Research Pipeline

The regulatory environment surrounding peptides in modern research, from simple chains to complex polypeptide hormones, changed materially in 2026. In February 2026, HHS announced that roughly 14 of 19 peptides on the FDA's restricted Category 2 compounding list would be returned to Category 1 status. By April 23, 2026, the FDA formally removed 12 peptides from that restricted list following Federal Register notices issued April 15-16.

However, compounds including BPC-157 and TB-500 remained on the restricted list and were scheduled for review by the FDA Peptide Compounding Advisory Committee in July 2026. These deliberations reflect the ongoing tension between research access and consumer safety in the compounding space.

On the clinical side, several milestones defined the period:

Oral semaglutide (25 mg) was approved in December 2025 for chronic weight management, extending polypeptide hormone therapy beyond injectables.
Orforglipron (Foundayo) was approved April 1, 2026, as the first oral, non-peptide GLP-1 receptor agonist, a product directly enabled by decades of polypeptide hormone biology research.
Palopegteriparatide (Yorvipath), a PEGylated parathyroid hormone prodrug, was approved in 2024 as the first treatment specifically for hypoparathyroidism, illustrating how complex polypeptide engineering enables long-acting endocrine therapies.
A peptide-based radiopharmaceutical was among the landmark approvals in Q1 2026, reflecting the growing use of conjugated peptides as diagnostic imaging agents.

Seven Phase 3 trial readouts are expected across 2026 in type 2 diabetes, sleep apnea, liver disease, and cardiovascular outcomes, most driven by incretin and hormone-mimetic peptide analogs.

For researchers evaluating metabolic peptides, the top 5 research peptides for metabolic health: an updated buyer's guide offers a curated overview of compounds with the strongest current research profiles.

Conclusion

The field of peptides in modern research, from simple chains to complex polypeptide hormones, is advancing on multiple fronts simultaneously. Short peptides like BPC-157 and GHK-Cu continue to generate data in tissue and cellular models. Mid-length compounds like MOTS-c are opening new windows into mitochondrial biology. And large polypeptide hormone analogs are reshaping clinical medicine in metabolic disease, endocrinology, and oncology.

Actionable next steps for researchers and professionals:

Audit the peptide compounds in your current research program against the updated 2026 FDA compounding classifications to ensure compliance.
Distinguish clearly between short peptides, polypeptides, and hormone analogs in experimental design, size and structure determine stability, dosing, and data interpretation.
Prioritize purity-verified, lab-tested peptide sources. Compound quality directly affects result reproducibility.
Monitor the FDA Peptide Compounding Advisory Committee outputs from mid-2026 onward, as these will continue to shape access to research compounds.
Explore the growing literature on mitochondrial peptides and multi-agonist hormone analogs, as these represent the most active areas of mechanistic discovery heading into 2027.

Complete Guide to Research Peptides: Types, Mechanisms, and Laboratory Use Cases

August 14, 2026/0 Comments/in Uncategorized/by

Over 7,000 naturally occurring peptides have been identified in the human body, yet the global research peptide market continues to expand as scientists uncover new ways these short amino acid chains regulate nearly every biological system. This complete guide to research peptides: types, mechanisms, and laboratory use cases is designed to serve as a foundational reference for researchers, students, and science professionals who need a clear, organized overview of how peptides are classified, how they work, and where they are being studied today.

Key Takeaways

Research peptides are short chains of 2 to 50 amino acids studied primarily in preclinical settings, with many lacking formal human approval.
Peptides are classified by their mechanism of action, including receptor agonism, membrane targeting, and enzyme modulation.
Major research categories include GLP-1 agonists, growth hormone secretagogues, regenerative peptides, neuropeptides, and longevity compounds.
Laboratory use cases span tissue repair, metabolic biology, angiogenesis, and mitochondrial function.
Formulation and stability challenges remain key areas of active investigation in peptide science.

What Are Research Peptides and How Are They Defined

Research peptides are amino acid chains typically ranging from 2 to 50 residues in length. This size range places them between small-molecule drugs and full-size proteins, giving them a distinct pharmacological profile. Most are studied in preclinical or early-phase settings, and many that appear in research catalogs have not received regulatory approval for human use.

Their appeal in laboratory research comes from several properties. Peptides can be synthesized with high precision, modified to improve stability, and designed to interact with specific receptors or cellular pathways. Unlike many small-molecule drugs, they often mimic endogenous signaling molecules, which makes them valuable tools for studying how biological systems respond to targeted stimulation or inhibition. For a deeper look at how these compounds compare with conventional pharmaceuticals, see Peptides vs Classic Small-Molecule Drugs.

Key structural features of research peptides:

Feature	Description
Chain length	2 to 50 amino acids
Molecular weight	Typically 500 to 5,000 Da
Synthesis method	Solid-phase peptide synthesis (SPPS)
Stability	Often sensitive to heat, light, and proteases
Selectivity	High receptor or pathway specificity

Major Types and Mechanistic Families in the Complete Guide to Research Peptides

Understanding peptide types requires looking at both structure and function. The most useful classification system in research settings groups peptides by their primary mechanism of action.

GLP-1 Agonists and Metabolic Peptides

GLP-1 receptor agonists are among the most clinically advanced peptide classes. They bind to glucagon-like peptide receptors to regulate insulin secretion, appetite, and energy metabolism. Newer multi-agonist designs, including triple-agonist compounds, are expanding the research scope considerably. The GLP-3 Retatrutide and triple-agonist peptides research overview covers how these next-generation compounds are reshaping metabolic science.

Growth Hormone Secretagogues

These peptides stimulate the pituitary gland to release growth hormone. Common examples include ipamorelin, sermorelin, and CJC-1295. They work primarily through ghrelin receptors or growth hormone-releasing hormone receptors. The CJC-1295 mechanism and pharmacokinetic comparison is a useful resource for understanding how DAC modification changes half-life and receptor interaction.

Regenerative and Tissue Repair Peptides

BPC-157 and TB-500 are the most widely studied compounds in this category. Research suggests they may influence angiogenesis, collagen synthesis, and cellular migration. The BPC-157 vs TB-500 complete research comparison provides a detailed side-by-side analysis of their proposed mechanisms and laboratory applications.

Neuropeptides and Cognitive Research Compounds

Selank, Semax, and BDNF-related peptides are studied for their roles in neuroplasticity, anxiety modulation, and cognitive function. These compounds interact with receptors in the central nervous system and are often administered intranasally in research settings. See the Selank peptide research benefits and mechanism of action for a detailed breakdown.

Longevity and Mitochondrial Peptides

MOTS-c, SS-31, and Epithalon represent a growing class of compounds studied for their effects on cellular aging, mitochondrial efficiency, and senescence pathways. The MOTS-c mitochondrial research themes page covers the current state of this research area.

Laboratory Use Cases Covered in This Complete Guide to Research Peptides

The practical applications of research peptides span multiple biological domains. Below are the primary laboratory use cases documented in current preclinical literature.

Tissue Repair and Regenerative Biology
Peptides such as BPC-157 are studied in wound healing models, tendon repair assays, and gut mucosal regeneration. Their proposed effects on nitric oxide pathways and growth factor upregulation make them valuable tools in regenerative biology research.

Metabolic and Endocrine Research
GLP-1 agonists and growth hormone secretagogues are used in metabolic studies examining insulin sensitivity, adipose tissue dynamics, and hormonal feedback loops. The complete guide to peptide mechanisms covering GLP-1 and growth hormone peptides explains the molecular detail behind these pathways.

Neuroprotection and Brain Research
Neuropeptides are used in models of neuroinflammation, cognitive decline, and stress response. Researchers study how these compounds modulate BDNF expression, serotonin signaling, and HPA axis activity.

Skin, Hair, and Connective Tissue Research
GHK-Cu and related copper-binding peptides are studied for their effects on collagen gene expression, antioxidant activity, and dermal repair. The GHK-Cu peptide and collagen research overview covers the current evidence base.

Mitochondrial and Aging Biology
SS-31 and MOTS-c are used in studies examining mitochondrial membrane potential, ROS production, and age-related cellular decline. These compounds are at the frontier of longevity research.

Formulation, Storage, and Administration Challenges

Peptides present unique challenges in research settings that differ significantly from small-molecule compounds.

Proteolytic degradation: Peptides are broken down rapidly by enzymes in biological fluids, requiring modified analogs or protective formulations.
Reconstitution accuracy: Lyophilized peptides must be reconstituted carefully to ensure dosing precision. Tools like peptide calculators help researchers maintain accuracy.
Storage requirements: Most research peptides require storage at -20°C or lower to maintain stability.
Routes of administration: Subcutaneous injection is most common in research models, though intranasal and oral routes are being studied for specific compounds.

"Stability and purity are the two most critical variables in peptide research. A compound that degrades before reaching its target cannot produce reliable data."

These formulation considerations are especially relevant when working with multi-peptide stacks or novel delivery systems currently under investigation.

Conclusion

This complete guide to research peptides: types, mechanisms, and laboratory use cases provides a working framework for understanding one of the most dynamic areas in modern biochemistry. As of 2026, hundreds of peptide compounds are under active preclinical and clinical evaluation, spanning metabolic disease, neurological research, regenerative medicine, and aging biology.

Actionable next steps for researchers:

Identify the mechanistic family most relevant to your research question before selecting a compound.
Review published preclinical data for your target peptide, paying close attention to model species and dosing protocols.
Confirm purity and third-party testing documentation before using any research peptide in a laboratory setting.
Consult regulatory guidance in your jurisdiction, as the legal status of research peptides varies by country and application.
Use the internal resources linked throughout this guide to explore specific peptide categories in greater depth.

Peptide science is advancing rapidly. Staying current with mechanistic research and emerging compound classes is essential for anyone working at the intersection of biochemistry, pharmacology, and translational medicine.

How 5-Amino-1MQ and MOTS-c Are Studied Together in Metabolic Research

August 13, 2026/0 Comments/in Uncategorized/by

Metabolic dysfunction now affects more than one billion people globally, yet the pipeline of approved pharmacological tools remains narrow. That gap has pushed researchers toward investigational compounds with complementary mechanisms, and few pairings have attracted more scientific curiosity in 2026 than 5-Amino-1MQ and MOTS-c. Understanding how 5-Amino-1MQ and MOTS-c are studied together in metabolic research requires looking at what each compound does independently before examining why their combination is considered scientifically interesting.

Key Takeaways

5-Amino-1MQ inhibits the enzyme NNMT, raising NAD+ levels and activating fat metabolism at the cellular level.
MOTS-c is a mitochondria-derived peptide that activates AMPK signaling and improves glucose handling in preclinical models.
The two compounds target different but interconnected metabolic pathways, making them a subject of combination research.
Both remain investigational; no randomized controlled trials in humans have confirmed fat-loss or metabolic outcomes for either agent.
Researchers and clinics are exploring stacking protocols with NAD+ precursors and GLP-1 agonists, though evidence remains early-stage.

The Distinct Mechanisms Behind Each Compound

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that consumes NAD+ precursors. When NNMT is blocked, cellular NAD+ availability rises. Higher NAD+ levels are associated with increased activity of sirtuins and other metabolic regulators that govern fat oxidation and energy expenditure. In adipose tissue, this shift appears to reduce lipid storage and promote lipolysis in cell and animal models. For a deeper look at how NAD+ connects to these peptide systems, the resource on adenosine triphosphate and mitochondrial peptides: how MOTS-c and 5-Amino-1MQ influence ATP production provides useful mechanistic context.

MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA. It primarily works through AMPK activation, a master energy sensor that promotes glucose uptake, suppresses lipogenesis, and enhances mitochondrial biogenesis. Unlike most peptides, MOTS-c can translocate to the nucleus under metabolic stress, where it modulates gene expression tied to metabolic flexibility. Researchers interested in its foundational biology can explore MOTS-c: the mitochondrial peptide for background on its discovery and signaling profile.

The key distinction is target specificity:

Feature	5-Amino-1MQ	MOTS-c
Primary target	NNMT enzyme	AMPK pathway
Key metabolite affected	NAD+	Glucose / lipid flux
Main tissue focus	Adipose tissue	Skeletal muscle, liver
Molecule type	Small molecule	Mitochondrial peptide
Administration route (research)	Oral (preclinical)	Injectable (preclinical)

How 5-Amino-1MQ and MOTS-c Are Studied Together in Metabolic Research: The Combination Rationale

The rationale for studying these two agents together is rooted in pathway complementarity. NNMT inhibition by 5-Amino-1MQ addresses the upstream availability of NAD+, while MOTS-c operates downstream through AMPK to improve how cells use the energy that NAD+ helps generate. In theory, raising NAD+ and simultaneously activating AMPK could produce additive effects on mitochondrial efficiency and substrate utilization.

Key insight: Researchers describe the pairing as targeting "two different floors of the same metabolic building", one compound improves fuel supply, the other improves how cells burn it.

Preclinical models examining this combination have focused on:

Adipose tissue remodeling, measuring changes in white adipose depots
Insulin sensitivity markers, fasting glucose, HOMA-IR in rodent models
Mitochondrial respiration assays, oxygen consumption rate in isolated cells
Body composition endpoints, lean mass preservation alongside fat reduction

Researchers studying related mitochondrial peptide combinations, such as the MOTS-c and Elamipretide pairing, have used similar assay frameworks, making that work a useful methodological reference point.

Evidence Tiers and Research Gaps

Both compounds remain firmly in the investigational category. Neither 5-Amino-1MQ nor MOTS-c is FDA-approved, and both are currently sold exclusively as research chemicals. The evidence base, as of mid-2026, sits at the following tiers:

Established (in vitro and animal data):

NNMT inhibition by 5-Amino-1MQ reduces adiposity in diet-induced obese mouse models
MOTS-c improves glucose tolerance and exercise capacity in aged rodents
Combination protocols in cell models suggest non-overlapping pathway activation

Emerging (mechanistic speculation and early protocol design):

Longevity-focused researchers have proposed NAD+/MOTS-c/5-Amino-1MQ stacks as a multi-target approach to metabolic aging
Clinics have begun positioning the duo for "weight plateau" scenarios alongside GLP-1 agonists, though this is protocol-level practice without controlled trial support

Missing (critical evidence gaps):

No randomized controlled trials in humans for either compound alone
No published human pharmacokinetic data for the combination
Organ-target interaction profiles at combined doses remain unstudied

Expert commentary from metabolic biology reviewers in 2026 consistently frames the situation as "interesting biology, weak human evidence." That honest assessment should anchor any research design that incorporates this pairing. For comparison, researchers interested in how appetite-modulating compounds are evaluated alongside metabolic peptides may find the analysis of tesofensine vs GLP-3 retatrutide appetite-modulating pathways instructive for study design principles.

How 5-Amino-1MQ and MOTS-c Are Studied Together: Protocol Design Considerations

For researchers designing combination studies, several practical considerations emerge from the existing preclinical literature.

Dosing sequencing: Some protocols administer 5-Amino-1MQ first to elevate NAD+ availability before introducing MOTS-c, hypothesizing that a primed NAD+ environment amplifies AMPK responsiveness. This sequencing remains theoretical but is gaining traction in research design discussions as of July 2026.

Biomarker selection: Researchers typically track NAD+/NADH ratios, phosphorylated AMPK levels, PGC-1 alpha expression, and mitochondrial membrane potential as primary readouts when studying this combination.

Stacking with other agents: A growing number of protocols layer this pairing with NAD+ precursors (NMN or NR) or GLP-1 receptor agonists. The MOTS-c and SLU-PP332 research context offers a parallel example of how MOTS-c is studied alongside exercise-mimetic compounds, which shares methodological overlap with 5-Amino-1MQ combination work.

Researchers comparing 5-Amino-1MQ against other weight-related compounds in isolation may also benefit from reviewing the 5-Amino-1MQ vs Tesofensine comparison to understand its standalone profile before interpreting combination data.

Conclusion

The study of how 5-Amino-1MQ and MOTS-c are examined together in metabolic research represents one of the more scientifically grounded areas of investigational peptide science in 2026. The mechanistic logic is sound: NNMT inhibition and AMPK activation address metabolic dysfunction from different but reinforcing angles. However, the evidence base remains preclinical, and the absence of human trial data is a significant limitation that no amount of mechanistic elegance can substitute.

Actionable next steps for researchers:

Ground any combination protocol in the existing rodent and cell-model literature before extrapolating to human applications.
Use validated biomarker panels (NAD+/NADH, p-AMPK, PGC-1 alpha) to generate quantifiable endpoints.
Source research-grade material with verified purity documentation, the MOTS-c peptide 10mg research-grade product page is one reference point for purity standards.
Monitor the clinical trial registries for emerging human studies, as this area is expected to move quickly given commercial and longevity-research interest.
Treat any "synergy" claims with appropriate skepticism until controlled human data is available.

The biology is compelling. The human evidence is not yet there. That gap is precisely what makes this combination a productive area for rigorous investigation.

5-Amino-1MQ and MOTS-c Synergy: What Combination Research Is Trying to Test in Metabolic Models

August 11, 2026/0 Comments/in Uncategorized/by

Metabolic disease research in 2026 faces a persistent problem: single-target interventions rarely replicate the complexity of conditions like obesity or insulin resistance. That gap is precisely why researchers are now designing experiments that pair 5-Amino-1MQ, a small-molecule NNMT inhibitor, with MOTS-c, a mitochondria-derived signaling peptide. The question driving this work is straightforward, does the 5-Amino-1MQ and MOTS-c synergy: what combination research is trying to test in metabolic models reveal anything that neither compound can show alone?

This article examines the mechanistic rationale behind that pairing, the hypotheses being constructed, and what meaningful synergy would actually look like in preclinical experimental settings.

Key Takeaways

5-Amino-1MQ inhibits NNMT, an enzyme linked to adipogenesis and reduced NAD+ availability, while MOTS-c is a mitochondrial peptide that activates AMPK and regulates glucose metabolism.
Researchers hypothesize that these two compounds may act on complementary, non-overlapping pathways, making combination testing scientifically rational.
Preclinical metabolic models are being used to probe potential synergy across three domains: adiposity reduction, insulin sensitivity, and energy expenditure.
Synergy, in a research context, means an effect greater than the sum of each compound's individual contribution, not simply additive benefit.
No human clinical data on this combination exists as of 2026; all discussion reflects hypothesis-driven preclinical research.

Understanding the Two Compounds Before Testing Synergy

What 5-Amino-1MQ Does in Metabolic Pathways

5-Amino-1MQ (5-amino-1-methylquinolinium) is a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme expressed heavily in adipose tissue. NNMT consumes S-adenosylmethionine (SAM) and converts nicotinamide into 1-methylnicotinamide. When NNMT is overactive, it depletes the methyl donor pool and reduces NAD+ precursor availability, two conditions associated with increased fat storage and impaired metabolic signaling.

By blocking NNMT, 5-Amino-1MQ is hypothesized to:

Restore SAM availability for epigenetic regulation
Increase NAD+ precursor flux, supporting sirtuin activity
Reduce adipocyte differentiation signals in vitro

For a deeper look at how this compound compares with classic mitochondrial pathway modulators, see the article on peptides and polypeptides in mitochondrial biology comparing MOTS-c and 5-Amino-1MQ.

What MOTS-c Does as a Mitochondrial Signal

MOTS-c is a 16-amino acid peptide encoded in the mitochondrial 12S rRNA. It functions as a retrograde signal, originating in mitochondria and traveling to the nucleus and cytoplasm to regulate gene expression. Its primary mechanism involves AMPK activation, which shifts cells toward fatty acid oxidation and glucose uptake.

Key research observations on MOTS-c include:

Improved insulin sensitivity in high-fat diet mouse models
Increased skeletal muscle glucose uptake independent of insulin
Translocation to the nucleus under metabolic stress, where it modifies gene expression

For a detailed comparison of MOTS-c with related mitochondrial peptides, the MOTS-c vs Humanin mitochondrial peptide comparison provides useful context.

The Mechanistic Case for 5-Amino-1MQ and MOTS-c Synergy in Metabolic Models

The central hypothesis is that these two compounds operate on distinct but converging nodes of metabolic regulation. 5-Amino-1MQ acts primarily at the epigenetic and substrate-availability level inside adipocytes. MOTS-c acts at the energy-sensing and glucose-uptake level, primarily in muscle and liver tissue.

This non-overlap is what makes the pairing scientifically interesting. Researchers are not testing two compounds that do the same thing, they are testing whether upstream epigenetic correction (via NNMT inhibition) combined with downstream mitochondrial energy signaling (via MOTS-c) produces effects that neither achieves independently.

Three core hypotheses under investigation:

Adiposity hypothesis: NNMT inhibition reduces fat cell formation while MOTS-c increases fat oxidation in existing adipocytes, together, they may reduce fat mass more effectively than either alone.
Insulin sensitivity hypothesis: 5-Amino-1MQ improves the intracellular environment for insulin signaling through SAM restoration; MOTS-c independently activates AMPK-driven glucose uptake. Combined, the effect on insulin sensitivity may be additive or synergistic.
Energy expenditure hypothesis: NAD+ restoration from NNMT inhibition supports mitochondrial biogenesis; MOTS-c directly activates AMPK. Both pathways increase energy expenditure, but through different rate-limiting steps.

This kind of multi-node targeting parallels strategies seen in other metabolic research designs. The article on cagrilintide synergy with GLP-1 illustrates how combination approaches are being applied across metabolic peptide research more broadly.

How Preclinical Models Are Designed to Test This Synergy

Model Selection and Endpoints

Most combination experiments in this space use diet-induced obesity (DIO) mouse models or db/db diabetic mice. These models allow researchers to measure:

Endpoint	Relevance to Combination Hypothesis
Body fat percentage	Tests adiposity hypothesis
Fasting glucose and HOMA-IR	Tests insulin sensitivity hypothesis
Oxygen consumption rate	Tests energy expenditure hypothesis
Adiponectin and leptin levels	Tracks adipokine signaling changes

Researchers also use in vitro adipocyte and myocyte co-culture systems to isolate cell-specific effects before moving to whole-animal models.

Defining Synergy vs. Additivity

A critical methodological point: synergy is not the same as a combined effect. In pharmacology, synergy means the combined outcome exceeds what would be predicted by adding each compound's individual effect. Researchers use the Bliss independence model or Loewe additivity framework to distinguish true synergy from simple additivity.

This distinction matters enormously for interpreting results. If both compounds reduce fasting glucose by 15% individually, and the combination reduces it by 35%, that gap of 5% beyond simple addition is where synergy claims begin.

For broader context on how peptide-based compounds are evaluated alongside small molecules in metabolic research, the top 5 research peptides for metabolic health buyer's guide covers the landscape well.

Dosing and Timing Variables

Combination research also requires careful attention to:

Sequence of administration (simultaneous vs. staggered dosing)
Dose-response curves for each compound alone before testing combinations
Duration of exposure given MOTS-c's short half-life relative to 5-Amino-1MQ's small-molecule stability

These variables are not minor. The wrong dosing sequence could mask synergy or create apparent antagonism where none exists.

For additional perspective on how small molecules fit alongside peptide-based approaches in metabolic study design, see tesofensine, enclomiphene, and peptide-based approaches in metabolic research.

What Meaningful Synergy Would Indicate for Future Research

If preclinical models confirm synergy across even one of the three hypotheses above, the implications for research design are significant. It would suggest that:

Epigenetic-level interventions (NNMT inhibition) can potentiate the effects of mitochondrial signaling peptides
Tissue-specific targeting, adipose vs. muscle, may be more important than systemic pathway coverage
Combination metabolic research deserves dedicated study arms rather than being treated as an afterthought

It would also raise new questions about optimal ratios, timing, and whether the synergy holds in aged or insulin-resistant models differently than in lean models. Researchers studying adjacent combination strategies, such as those reviewed in polypeptide peptides in cardiometabolic models, face similar interpretive challenges.

Conclusion

The scientific rationale for testing 5-Amino-1MQ and MOTS-c synergy: what combination research is trying to test in metabolic models is mechanistically sound. These two compounds address metabolic dysfunction through non-overlapping pathways, one at the epigenetic and substrate level, the other at the mitochondrial energy-sensing level. That complementarity is exactly what makes combination testing worthwhile.

Actionable next steps for researchers and research readers:

Review existing single-compound dose-response data for both 5-Amino-1MQ and MOTS-c before interpreting combination results
Apply formal synergy frameworks (Bliss or Loewe) rather than assuming combined effects equal synergy
Track endpoint specificity, adiposity, insulin sensitivity, and energy expenditure may respond differently to the combination
Monitor peer-reviewed literature from 2026 onward as DIO model data from combination arms begins to emerge

This is hypothesis-driven science at an early stage. The value lies not in premature conclusions, but in the quality of the questions being asked.

5-Amino-1MQ Peptide: Mechanism, Metabolic Research, and How It Differs From Mitochondrial Peptides

August 10, 2026/0 Comments/in Uncategorized/by

}

Only about 15% of ingested NAD+ precursors reach intracellular compartments where they can actually drive energy metabolism, a bottleneck that has pushed researchers toward upstream enzyme inhibitors as a more direct intervention point. That upstream target is NNMT, and the compound drawing the most research attention in 2026 is 5-Amino-1MQ. This article breaks down the 5-Amino-1MQ peptide: mechanism, metabolic research, and how it differs from mitochondrial peptides, answering the mechanism questions that efficacy summaries typically skip.

Key Takeaways

5-Amino-1MQ is technically a small-molecule NNMT inhibitor, not a peptide, though it is frequently grouped with metabolic peptide stacks in research literature.
Its primary mechanism involves blocking NNMT-driven NAD+ consumption, which raises intracellular NAD+ availability and activates SIRT1 signaling.
Preclinical models show significant effects on adipocyte differentiation, lipid accumulation, and energy expenditure.
Mitochondrial peptides such as MOTS-c and SS-31 work through distinct receptor-level and membrane-targeting pathways that do not overlap with NNMT inhibition.
Understanding these mechanistic differences matters for designing multi-compound research protocols.

What Is 5-Amino-1MQ and Why the "Peptide" Label Persists

Before diving into mechanism, a classification note is worth making. 5-Amino-1MQ, full name 5-amino-1-methylquinolinium, is a small-molecule inhibitor, not a peptide. It has no amino acid chain, no peptide bond, and no receptor-binding motif typical of endogenous peptides. The "peptide" label persists because researchers and suppliers frequently group it with metabolic peptide stacks, and because its functional territory overlaps with compounds like MOTS-c.

This distinction matters for protocol design. For a broader look at how different compound classes interact at the cellular level, the overview of peptides mechanism from GLP-3 retatrutide to CJC-1295 and MOTS-c provides useful framing.

5-Amino-1MQ's molecular target is nicotinamide N-methyltransferase (NNMT), an enzyme highly expressed in adipose tissue that consumes S-adenosylmethionine (SAM) and NAD+ precursors during methylation reactions. When NNMT is overactive, it depletes both SAM and the NAD+ pool, suppressing SIRT1 activity and impairing mitochondrial function.

The Core Mechanism: NNMT Inhibition and NAD+ Restoration

The mechanistic chain is straightforward once broken into steps:

NNMT inhibition, 5-Amino-1MQ binds competitively to the NNMT active site, reducing the enzyme's ability to methylate nicotinamide.
NAD+ precursor conservation, With less nicotinamide consumed by NNMT, more substrate feeds into the NAD+ biosynthesis pathway via NAMPT.
SIRT1 activation, Elevated intracellular NAD+ activates SIRT1, a deacetylase that regulates metabolic gene expression, mitochondrial biogenesis, and fat oxidation.
SAM preservation, Reduced NNMT activity also conserves SAM, supporting methylation reactions involved in epigenetic regulation and one-carbon metabolism.

"The compound does not donate NAD+ directly, it removes the enzymatic drain that prevents NAD+ from accumulating in the first place."

This indirect restoration model is mechanistically different from NAD+ precursor supplementation (NMN, NR), which adds substrate without addressing the enzymatic drain. For a deeper look at how NAD+ interacts with mitochondrial peptide research, the article on adenosine triphosphate and mitochondrial peptides including MOTS-c and 5-Amino-1MQ covers ATP production endpoints in detail.

Key Molecular Effects Observed in Preclinical Models

Effect	Observed Outcome
NNMT inhibition	Reduced nicotinamide methylation in adipocytes
Intracellular NAD+	Elevated in treated cell lines
SIRT1 activity	Upregulated downstream of NAD+ increase
Adipocyte lipid accumulation	Reduced in differentiation assays
Energy expenditure markers	Increased in diet-induced obesity models

Metabolic Research Findings: Adipose Tissue and Energy Balance

Preclinical research on 5-Amino-1MQ has concentrated on white adipose tissue (WAT), where NNMT expression is highest. In rodent models of diet-induced obesity, NNMT inhibition with 5-Amino-1MQ has been associated with:

Reduced fat mass without significant lean mass changes
Increased expression of thermogenic markers in adipose depots
Improved insulin sensitivity in metabolically compromised models
Upregulation of mitochondrial biogenesis genes

These findings position 5-Amino-1MQ within a broader class of metabolic research tools that target energy balance from the cellular level upward. Researchers comparing it against appetite-modulating compounds should note that its mechanism is entirely peripheral, there is no central nervous system component in current models. For contrast, the article on tesofensine and metabolic research comparing noradrenergic appetite modulators with GLP-3 peptides illustrates how centrally acting compounds differ in study design.

The peptides and polypeptides overview connecting DNA, mitochondria, and research compounds like MOTS-c and 5-Amino-1MQ also contextualizes where NNMT inhibitors fit within the broader mitochondrial research landscape.

How 5-Amino-1MQ Differs From Mitochondrial Peptides

This is where the 5-Amino-1MQ peptide: mechanism, metabolic research, and how it differs from mitochondrial peptides question becomes most practically relevant for researchers designing stacks or comparative studies.

Mitochondrial peptides, including MOTS-c, Humanin, and SS-31, are short amino acid sequences encoded in mitochondrial DNA or designed to target mitochondrial membranes. Their mechanisms include:

MOTS-c: Translocates to the nucleus under metabolic stress, activating AMPK and regulating folate and methionine metabolism
SS-31 (Elamipretide): Targets cardiolipin on the inner mitochondrial membrane, reducing oxidative stress and improving electron transport chain efficiency
Humanin: Binds cell-surface receptors and acts as a cytoprotective signaling molecule

5-Amino-1MQ, by contrast:

Has no amino acid structure
Does not interact with mitochondrial membranes directly
Does not bind peptide receptors
Works entirely through enzyme inhibition in the cytoplasm

This means the two compound classes are mechanistically complementary rather than redundant. A protocol pairing 5-Amino-1MQ with MOTS-c, for example, could theoretically address both the NAD+ depletion problem (via NNMT inhibition) and the downstream mitochondrial signaling deficit (via MOTS-c's AMPK activation). Researchers interested in SS-31's distinct membrane-targeting mechanism can explore SS-31 peptide research resources for comparison data.

For researchers sourcing compounds for metabolic studies, lab-tested peptides with verified purity documentation are essential for reproducible results.

Conclusion

5-Amino-1MQ occupies a unique position in the 2026 metabolic research landscape: it is not a peptide, but it operates in the same functional territory as mitochondrial peptides by restoring the NAD+ environment that those peptides depend on. Its mechanism, competitive NNMT inhibition leading to NAD+ conservation, SIRT1 activation, and improved adipose tissue metabolism, is well-defined at the preclinical level and mechanistically distinct from compounds like MOTS-c or SS-31.

Actionable next steps for researchers:

Review NNMT expression data in your specific tissue model before including 5-Amino-1MQ in a protocol
Consider pairing with a mitochondrial peptide to address both upstream NAD+ availability and downstream membrane-level function
Verify compound purity through third-party COA documentation before initiating any in vitro or in vivo work
Design controls that isolate NNMT inhibition from NAD+ precursor supplementation to avoid confounded endpoints

Understanding the mechanistic boundaries of each compound class, not just their reported outcomes, is what separates rigorous research design from assumption-driven stacking.

5-Amino-1MQ and MOTS-c Synergy: How Mitochondrial Pathways Are Studied Together

August 7, 2026/0 Comments/in Uncategorized/by

Mitochondrial dysfunction now appears in the pathophysiology of more than 150 human diseases, yet most research still examines metabolic compounds one at a time. That single-compound approach misses something important: inside living cells, energy-regulating molecules rarely act alone. The growing body of research around 5-Amino-1MQ and MOTS-c synergy: how mitochondrial pathways are studied together reflects a deliberate shift toward multi-target experimental frameworks, and the early data explain why.

Key Takeaways

5-Amino-1MQ inhibits NNMT, raising cellular NAD+ and SAM levels, while MOTS-c activates AMPK and regulates mitochondrial gene expression.
Researchers pair these two compounds because their mechanisms are complementary rather than redundant.
Adiposity models and metabolic disease frameworks are the most common contexts for studying this combination.
Translational questions about aging, obesity, and insulin sensitivity drive much of the current experimental design.
Purity and sourcing quality are critical variables when designing reproducible multi-compound studies.

What Is 5-Amino-1MQ and Why Does It Matter for Mitochondrial Research

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT is an enzyme found in high concentrations in adipose tissue. When NNMT is overactive, it consumes S-adenosyl methionine (SAM) and reduces cellular NAD+ availability, two outcomes that suppress mitochondrial efficiency.

By blocking NNMT, 5-Amino-1MQ effectively raises the intracellular pool of both NAD+ and SAM. Higher NAD+ levels feed into sirtuin pathways (particularly SIRT1 and SIRT3), which regulate mitochondrial biogenesis, fatty acid oxidation, and cellular stress responses.

Key mechanisms under study:

NNMT inhibition and NAD+ restoration
Sirtuin pathway activation downstream of elevated NAD+
Reduction of adipocyte hypertrophy in white adipose tissue
Potential effects on beige adipose tissue phenotype conversion

In preclinical models, 5-Amino-1MQ has shown measurable reductions in fat mass without caloric restriction, which makes it particularly relevant for obesity and metabolic syndrome research frameworks.

What Is MOTS-c and How Does It Interact With Cellular Energy Systems

MOTS-c is a mitochondria-derived peptide (MDP) encoded within the 12S rRNA region of mitochondrial DNA. Unlike most peptides, it is not encoded by nuclear DNA, it originates inside the mitochondria themselves. This origin makes MOTS-c a direct signal of mitochondrial status.

MOTS-c activates AMP-activated protein kinase (AMPK), the master energy sensor of the cell. AMPK activation triggers a cascade that includes:

Increased glucose uptake in skeletal muscle
Suppression of de novo lipogenesis
Enhanced mitochondrial fatty acid oxidation
Regulation of the folate cycle and methionine metabolism

Researchers studying MOTS-c alongside elamipretide have noted that mitochondria-targeted compounds can produce additive effects when their mechanisms address different nodes of the same pathway network.

MOTS-c levels decline with age and in states of metabolic stress, which positions it as both a biomarker and a potential research tool in aging and obesity models.

Studying 5-Amino-1MQ and MOTS-c Synergy: How Mitochondrial Pathways Are Studied Together

The central question researchers ask when designing co-administration experiments is: do these compounds address the same bottleneck, or different ones? If two compounds share a single mechanism, combining them offers little additional insight. If they act at distinct but connected nodes, the combination reveals pathway architecture that single-compound studies cannot.

5-Amino-1MQ and MOTS-c address different nodes:

Compound	Primary Target	Downstream Effect
5-Amino-1MQ	NNMT enzyme inhibition	Raises NAD+, activates sirtuins
MOTS-c	AMPK activation	Improves glucose uptake, reduces lipogenesis

Because NAD+-sirtuin signaling and AMPK signaling both converge on mitochondrial biogenesis and fatty acid oxidation, the two pathways are complementary, not redundant. This is the core rationale for studying them together.

"Combining compounds with distinct but convergent mechanisms allows researchers to map the actual topology of metabolic networks rather than just confirming that a single node matters."

Experimental Models Used in Synergy Research

Researchers typically use three types of models to study this combination:

Adiposity and obesity models, High-fat diet rodent models where both fat mass reduction and insulin sensitivity can be measured simultaneously.
Aging models, Aged cell cultures or animal models where declining NAD+ and MOTS-c levels can be artificially restored.
Skeletal muscle energy models, Focused on glucose uptake efficiency and mitochondrial respiration rates.

In adiposity models specifically, the combination of NNMT inhibition (raising NAD+) and AMPK activation (suppressing fat synthesis) creates a dual pressure on adipocyte metabolism. This is why the SS-31 elamipretide research community, which also focuses on mitochondrial membrane integrity, has begun watching MOTS-c co-administration data closely.

Translational Questions Driving the Research

The translational questions are direct:

Can restoring both NAD+ availability and AMPK activity simultaneously produce greater metabolic correction than either alone?
Does the combination affect insulin sensitivity additively or synergistically?
Are there tissue-specific differences in how the two pathways interact in muscle versus adipose tissue?

These questions are not yet fully answered. Most current data come from preclinical models, and rigorous dose-response mapping for the combination remains an active area. Researchers sourcing compounds for these studies consistently prioritize verified purity, a variable that becomes even more critical when interpreting multi-compound results. Sourcing from a best peptide manufacturer with documented testing reduces confounding variables in experimental design.

Methodological Considerations for Multi-Compound Mitochondrial Studies

Designing a valid co-administration study requires more than simply administering both compounds. Several methodological factors determine whether the data will be interpretable.

Critical design variables include:

Dosing sequence and timing, Whether compounds are administered simultaneously or in sequence affects which pathway activates first and whether downstream signals interfere.
Readout selection, Measuring only body weight misses mechanistic data. Researchers typically track NAD+/NADH ratios, AMPK phosphorylation status, oxygen consumption rates (OCR), and adipocyte morphology.
Compound purity, Impurities in either compound introduce confounding signals. Researchers also examining SS-31 kidney health research have documented how trace contaminants skew mitochondrial respiration readings.
Model selection, In vitro models confirm mechanism but cannot capture systemic metabolic feedback loops that appear in vivo.

A related consideration is how findings from MOTS-c and 5-Amino-1MQ studies connect to broader peptide combination research. Work on compounds like TB-500 and BPC-157 has established methodological templates for multi-peptide experimental designs that the mitochondrial research community is now adapting.

Researchers also note that the wholesale peptides for sale market varies significantly in quality, and batch-to-batch consistency is a non-negotiable requirement when designing longitudinal studies.

Conclusion

The research framework around 5-Amino-1MQ and MOTS-c synergy: how mitochondrial pathways are studied together represents a meaningful evolution in metabolic science. Rather than asking whether a single compound affects mitochondrial function, researchers are now mapping how complementary mechanisms interact across the NAD+-sirtuin and AMPK networks simultaneously.

Actionable next steps for researchers and informed readers:

Review published preclinical data on NNMT inhibition and AMPK activation in adiposity models before designing new experiments.
Prioritize sourcing compounds from manufacturers with third-party purity documentation to ensure reproducible results.
Design readout panels that capture both sirtuin pathway markers and AMPK phosphorylation status to detect true synergy rather than simple additive effects.
Monitor translational literature closely, human-relevant data on this combination is emerging in 2026 and will likely reshape experimental protocols.

Understanding how these two mitochondrial pathways interact is not just a mechanistic question. It is the foundation for developing more precise interventions in metabolic disease, aging, and obesity research.

5-Amino-1MQ and MOTS-c Synergy: How Mitochondrial Peptides Target Adiposity and Insulin Resistance in Experimental Models

August 5, 2026/0 Comments/in Uncategorized/by

Metabolic dysfunction now affects more than one billion people worldwide, yet the molecular machinery driving fat accumulation and insulin resistance remains only partially mapped. Two research compounds, 5-Amino-1MQ and MOTS-c, are drawing serious attention in 2026 precisely because they appear to converge on that machinery from complementary angles. The study of 5-Amino-1MQ and MOTS-c synergy: how mitochondrial peptides target adiposity and insulin resistance in experimental models offers a mechanistic lens that goes well beyond conventional metabolic research.

Key Takeaways

5-Amino-1MQ inhibits NNMT, reducing fat cell formation and improving energy expenditure in preclinical models.
MOTS-c is a mitochondria-derived peptide that activates AMPK and improves insulin sensitivity in animal studies.
Both compounds influence overlapping metabolic pathways, suggesting additive or synergistic effects when combined.
Preclinical data support their combined use as a research framework for studying adiposity and glucose regulation.
Neither compound is approved for human therapeutic use; all findings are restricted to experimental research contexts.

What Are 5-Amino-1MQ and MOTS-c?

5-Amino-1MQ: An NNMT Inhibitor

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT is an enzyme highly expressed in white adipose tissue. When overactive, it drains the NAD+ precursor pool and suppresses cellular energy expenditure.

By blocking NNMT, 5-Amino-1MQ:

Raises intracellular SAM (S-adenosylmethionine) levels
Increases NAD+ availability
Reduces adipogenesis (new fat cell formation)
Enhances resting metabolic rate in diet-induced obesity mouse models

A landmark study by Neelakantan et al. (2019) demonstrated that NNMT inhibition with a structurally related compound reduced fat mass and improved metabolic markers without altering food intake in obese mice, a finding that positioned NNMT inhibitors as promising anti-obesity research tools.

MOTS-c: A Mitochondrial Microprotein

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino acid peptide encoded within mitochondrial DNA. It is not a synthetic invention, it is naturally produced in human tissue and declines with age and metabolic stress.

MOTS-c primarily works by:

Activating AMPK (AMP-activated protein kinase), the master energy sensor
Improving skeletal muscle glucose uptake
Reducing hepatic lipid accumulation
Modulating the folate cycle and methionine metabolism

Research published by Lee et al. (2015) showed that MOTS-c administration improved insulin sensitivity and reduced obesity in high-fat diet mouse models. Subsequent studies confirmed its role as an exercise-mimetic signal, released during physical exertion to coordinate systemic metabolic adaptation.

For researchers exploring related mitochondrial peptide interactions, the MOTS-c and elamipretide research overview provides useful comparative context. Similarly, SS-31 mitochondrial dynamics research illustrates how mitochondria-targeted compounds share overlapping mechanisms.

Mechanistic Overlap: Where the Pathways Converge

Understanding 5-Amino-1MQ and MOTS-c synergy in targeting adiposity and insulin resistance requires mapping where their pathways intersect.

AMPK as the Central Node

Both compounds ultimately elevate AMPK activity, though through different upstream routes:

Compound	Primary Target	Route to AMPK Activation
5-Amino-1MQ	NNMT enzyme	Raises NAD+, activates SIRT1/AMPK axis
MOTS-c	Mitochondrial signaling	Direct AMPK phosphorylation in muscle

Elevated AMPK suppresses lipogenesis, promotes fatty acid oxidation, and enhances GLUT4 translocation, the glucose transporter responsible for insulin-stimulated glucose uptake in muscle.

NAD+ and Methionine Cycle Crosstalk

5-Amino-1MQ increases SAM availability by reducing NNMT-driven methylation drain. MOTS-c independently modulates the folate-methionine cycle. In combination, preclinical logic suggests they may produce a more sustained elevation of metabolic cofactors than either agent alone.

"Compounds that converge on AMPK and NAD+ metabolism from distinct upstream nodes represent a rational basis for combination research designs in metabolic disease models."

Adipogenesis Suppression

5-Amino-1MQ directly reduces the differentiation of preadipocytes into mature fat cells. MOTS-c reduces lipid accumulation in liver and muscle. Together, they may address both peripheral fat storage and ectopic lipid deposition, two distinct but interrelated drivers of insulin resistance.

Researchers interested in peptide combinations targeting metabolic pathways may also find value in reviewing the synergy of LL-37 and SS-31 as a model for how mechanistically distinct peptides can complement each other.

Experimental Evidence and Research Design Considerations

Preclinical Findings

In diet-induced obesity (DIO) mouse models, NNMT inhibitors have consistently reduced:

Adipose tissue mass by 15-30% over 4-8 week protocols
Fasting insulin levels
Hepatic triglyceride content

MOTS-c administration in similar DIO models has shown:

Improved glucose tolerance test (GTT) results within 2 weeks
Reduced HOMA-IR scores (a measure of insulin resistance)
Increased mitochondrial biogenesis markers in skeletal muscle

Combination Research Design Notes

When designing experiments to study 5-Amino-1MQ and MOTS-c synergy in experimental models targeting adiposity and insulin resistance, researchers typically consider:

Dose sequencing, whether to co-administer or stagger dosing
Tissue-specific readouts, adipose, liver, and skeletal muscle panels
Biomarker selection, AMPK phosphorylation, NAD+/NADH ratio, GLUT4 expression
Model selection, DIO vs. genetic obesity models (e.g., db/db mice)

Researchers exploring growth hormone secretagogue combinations for metabolic endpoints may also reference tesa peptide benefits and AOD-9604 research method notes for comparative fat-loss mechanism data.

For broader metabolic peptide context, GLP-1 peptide research and GLP-3 retratrutide research represent parallel pathways targeting adiposity through incretin mechanisms.

Conclusion

The mechanistic case for studying 5-Amino-1MQ and MOTS-c synergy, how mitochondrial peptides target adiposity and insulin resistance in experimental models, is grounded in converging biology. Both compounds act on AMPK, NAD+ metabolism, and lipid regulation through distinct but complementary upstream routes. Preclinical data from independent studies on each agent are promising, and the rationale for combination protocols is scientifically coherent.

Actionable next steps for researchers:

Review published NNMT inhibitor and MOTS-c literature to establish baseline biomarker panels before designing combination studies.
Select DIO mouse models with well-characterized insulin resistance phenotypes for maximum translational relevance.
Include tissue-specific mitochondrial function assays (e.g., oxygen consumption rate) alongside standard metabolic endpoints.
Consult current IRB and institutional guidelines, neither compound has regulatory approval for human use.

As metabolic research tools, 5-Amino-1MQ and MOTS-c represent a compelling frontier for understanding how the mitochondria-adipose axis can be modulated at the molecular level.

Peptides and Polypeptides in Mitochondrial Biology: How MOTS-c and 5-Amino-1MQ Compare With Classic Mitochondrial Pathways

August 1, 2026/0 Comments/in Uncategorized/by

Mitochondria consume roughly 90% of the oxygen a cell uses, yet the molecular signals that govern their health remain one of biology's most active research frontiers. Exploring peptides and polypeptides in mitochondrial biology: how MOTS-c and 5-Amino-1MQ compare with classic mitochondrial pathways gives researchers a sharper map of where newer mitochondria-targeted compounds sit relative to well-established mechanisms like oxidative phosphorylation, the electron transport chain (ETC), and mitochondrial biogenesis.

Key Takeaways

Mitochondria rely on canonical pathways, the ETC, ATP synthase, and PGC-1alpha-driven biogenesis, to sustain cellular energy.
MOTS-c is a mitochondria-derived peptide (MDP) encoded in mitochondrial DNA that activates AMPK and influences metabolic homeostasis.
5-Amino-1MQ is a small-molecule NNMT inhibitor that raises NAD+ precursor availability, indirectly supporting mitochondrial function.
Both agents intersect classic pathways at distinct nodes, making their mechanisms complementary rather than redundant.
Ongoing preclinical research continues to clarify how these compounds compare with established mitochondrial targets such as SS-31 (elamipretide).

Classic Mitochondrial Pathways: The Baseline for Comparison

Before mapping newer peptide research, it helps to anchor the discussion in core mitochondrial biology.

Oxidative phosphorylation (OXPHOS) is the process by which electrons from NADH and FADH2 travel through five protein complexes embedded in the inner mitochondrial membrane. This electron flow drives proton pumping, creating a gradient that ATP synthase (Complex V) converts into ATP, the cell's primary energy currency.

Mitochondrial biogenesis is the regulated growth and division of mitochondria. The transcriptional coactivator PGC-1alpha sits at the top of this regulatory cascade, coordinating nuclear respiratory factors (NRF-1, NRF-2) and mitochondrial transcription factor A (TFAM) to replicate mitochondrial DNA and build new organelles.

AMPK (AMP-activated protein kinase) acts as a cellular energy sensor. When the AMP:ATP ratio rises, signaling low energy, AMPK activates PGC-1alpha, stimulates fatty acid oxidation, and suppresses anabolic pathways that consume ATP.

NAD+ metabolism links directly to both OXPHOS and biogenesis. NAD+ is the electron acceptor that feeds Complex I of the ETC; it also activates sirtuins (SIRT1, SIRT3) that deacetylate and activate PGC-1alpha. Declining NAD+ is a hallmark of cellular aging and metabolic dysfunction.

These four nodes, OXPHOS, biogenesis via PGC-1alpha, AMPK signaling, and NAD+ flux, form the reference framework against which MOTS-c and 5-Amino-1MQ can be evaluated.

MOTS-c and 5-Amino-1MQ: Mechanisms Within Mitochondrial Pathways

MOTS-c: A Mitochondria-Derived Peptide With AMPK Activity

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the 12S rRNA gene of mitochondrial DNA. Its discovery in 2015 by Lee et al. established a new class of signaling molecules: mitochondria-derived peptides (MDPs).

Key mechanistic points:

AMPK activation: MOTS-c translocates to the nucleus under metabolic stress and activates AMPK, mirroring the energy-sensing role that classic AMPK activators (e.g., AICAR, metformin) fulfill.
Folate cycle interference: MOTS-c inhibits the folate cycle and de novo purine synthesis, which raises AMP levels and secondarily activates AMPK, a unique upstream mechanism not shared by conventional AMPK agonists.
Metabolic homeostasis: Preclinical studies show MOTS-c improves insulin sensitivity and reduces diet-induced obesity in mouse models, consistent with enhanced mitochondrial substrate utilization.

Compared to the classic PGC-1alpha pathway, MOTS-c does not directly upregulate mitochondrial biogenesis genes. Instead, it optimizes existing mitochondrial function by shifting cellular metabolism toward fatty acid oxidation and away from glucose dependence.

5-Amino-1MQ: NAD+ Restoration Through NNMT Inhibition

5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that consumes S-adenosylmethionine (SAM) and converts nicotinamide into 1-methylnicotinamide, effectively sequestering NAD+ precursors away from biosynthetic use.

By blocking NNMT, 5-Amino-1MQ:

Increases intracellular nicotinamide availability, boosting NAD+ biosynthesis via the salvage pathway.
Elevates SIRT1 and SIRT3 activity, which deacetylates and activates PGC-1alpha, linking this compound directly to mitochondrial biogenesis.
Reduces adipogenesis in preclinical models, an effect attributed to improved mitochondrial energy expenditure.

Unlike direct NAD+ precursors (NMN, NR), 5-Amino-1MQ acts upstream by preventing precursor loss rather than supplying additional substrate. This positions it at a distinct node within NAD+ metabolism.

Comparing Peptides and Polypeptides in Mitochondrial Biology: MOTS-c, 5-Amino-1MQ, and SS-31

Understanding peptides and polypeptides in mitochondrial biology: how MOTS-c and 5-Amino-1MQ compare with classic mitochondrial pathways becomes clearer when these agents are placed alongside SS-31 (elamipretide), a well-studied mitochondria-targeted peptide. Researchers exploring SS-31 mitochondrial dynamics will recognize that SS-31 operates primarily at the inner mitochondrial membrane, stabilizing cardiolipin and protecting the structural integrity of ETC complexes, a mechanism distinct from both MOTS-c and 5-Amino-1MQ.

Agent	Primary Target	Classic Pathway Node
MOTS-c	AMPK activation	Energy sensing / substrate utilization
5-Amino-1MQ	NNMT inhibition	NAD+ metabolism / biogenesis
SS-31	Cardiolipin stabilization	ETC structural integrity

Those researching SS-31 elamipretide will find that its cardiolipin-targeting mechanism complements MOTS-c's metabolic signaling role rather than overlapping with it. Similarly, resources on SS-31 mechanism and research provide useful context for understanding how structural mitochondrial peptides differ from signaling MDPs.

For researchers building a broader peptide research framework, reviewing research-only peptides and quality peptides sourcing considerations remains an essential step before experimental design. Aging-focused research programs may also find value in the aging support product category when planning compound selection.

Where the Mechanisms Converge

Despite their distinct entry points, all three agents ultimately support mitochondrial efficiency:

MOTS-c and 5-Amino-1MQ both feed into PGC-1alpha activity, MOTS-c via AMPK upstream signaling and 5-Amino-1MQ via SIRT1 activation downstream of NAD+.
SS-31 preserves the structural platform (cristae morphology, cardiolipin integrity) on which OXPHOS complexes operate.
Together, they represent complementary layers: structural protection, energy sensing, and metabolic substrate management.

Conclusion

Mapping peptides and polypeptides in mitochondrial biology: how MOTS-c and 5-Amino-1MQ compare with classic mitochondrial pathways reveals a layered picture. MOTS-c engages the AMPK energy-sensing node through a novel folate-cycle mechanism, while 5-Amino-1MQ restores NAD+ precursor flux by blocking NNMT, each intersecting canonical pathways at a different control point. Neither replaces the foundational biology of OXPHOS or PGC-1alpha-driven biogenesis; both modulate it.

Actionable next steps for researchers in 2026:

Establish baseline NAD+ and AMPK activity measurements in your model system before introducing either compound.
Consider whether structural mitochondrial protection (SS-31) should precede or accompany metabolic signaling interventions.
Review current preclinical literature on MOTS-c dosing windows and 5-Amino-1MQ selectivity profiles before experimental design.
Source compounds from verified, tested suppliers and document purity certificates for all research-grade materials.

The intersection of mitochondrial peptide biology with classic energy pathways is one of the most promising areas in cellular research today, and understanding where each tool fits within that map is the first step toward rigorous, reproducible science.

References

Lee, C., et al. (2015). "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism, 21(3), 443-454.
Neinast, M., et al. (2019). "Quantitative Analysis of the Whole-Body Metabolic Fate of Branched-Chain Amino Acids." Cell Metabolism, 29(2), 417-429.
Hong, S., et al. (2021). "NAD+ metabolism and its roles in cellular processes during ageing." Nature Reviews Molecular Cell Biology, 22(2), 119-141.
Bhullar, K. S., & Hubbard, B. P. (2015). "Lifespan and healthspan extension by resveratrol." Biochimica et Biophysica Acta, 1852(6), 1209-1218.
Szeto, H. H. (2014). "First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics." British Journal of Pharmacology, 171(8), 2029-2050.
Eckert, M. A., et al. (2019). "Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts." Nature, 569(7758), 723-728.